miR-6077 promotes cisplatin/pemetrexed resistance in lung adenocarcinoma via CDKN1A/cell cycle arrest and KEAP1/ferroptosis pathways

• Príomhchruthaitheoirí: Guoshu Bi (Údar), Jiaqi Liang (Údar), Mengnan Zhao (Údar), Huan Zhang (Údar), Xing Jin (Údar), Tao Lu (Údar), Yuansheng Zheng (Údar), Yunyi Bian (Údar), Zhencong Chen (Údar), Yiwei Huang (Údar), Valeria Besskaya (Údar), Cheng Zhan (Údar), Qun Wang (Údar), Lijie Tan (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: Elsevier, 2022-06-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

Lung adenocarcinoma (LUAD) is one of the most common malignancies worldwide. Combination chemotherapy with cisplatin (CDDP) plus pemetrexed (PEM) remains the predominant therapeutic regimen; however, chemoresistance greatly limits its curative potential. Here, through CRISPR-Cas9 screening, we ident...